Frontiers in cardiovascular medicine · 2026
Impact of COVID-19 history on the prevalence of coronary slow flow: a comparative study in unstable angina patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alan Sait, Alan Bircan
Аннотация
AIM: This study investigated coronary slow flow (CSF) prevalence in post-COVID-19 patients presenting with unstable angina (UA) and angiographically normal coronary arteries.
MATERIALS AND METHODS: The study included 190 patients presenting with unstable angina (UA) and confirmed normal coronary arteries via invasive angiography. Participants were divided into two age- and sex-matched groups: 95 patients with a history of COVID-19 [COVID (+) UA-NCA] and 95 patients without a prior history of the infection [COVID (-) UA-NCA]. In the study group, COVID-19 was confirmed via RT-PCR and computed tomography. All participants underwent coronary angiography to perform Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) measurements. CSF was diagnosed in patients with a corrected TFC (CTFC) ≥ 27.
RESULTS: CSF prevalence was significantly higher in the COVID (+) UA-NCA group than in the COVID (-) UA-NCA group (18.9% vs. 5.3%, p = 0.003). Individual CTFC values for the LAD, LCX, and RCA were also significantly higher in the COVID (+) UA-NCA group compared to the COVID (-) UA-NCA group (26.1 ± 4.3 vs. 22.4 ± 2.6 [p = 0.01], 24.3 ± 4.5 vs. 21.7 ± 2.4 [p < 0.001], and 24.3 ± 4.5 vs. 21.4 ± 2.5 [p < 0.001], respectively).
CONCLUSIONS: CSF prevalence is significantly higher in patients with a history of COVID-19, suggesting persistent microvascular impairment.
MATERIALS AND METHODS: The study included 190 patients presenting with unstable angina (UA) and confirmed normal coronary arteries via invasive angiography. Participants were divided into two age- and sex-matched groups: 95 patients with a history of COVID-19 [COVID (+) UA-NCA] and 95 patients without a prior history of the infection [COVID (-) UA-NCA]. In the study group, COVID-19 was confirmed via RT-PCR and computed tomography. All participants underwent coronary angiography to perform Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) measurements. CSF was diagnosed in patients with a corrected TFC (CTFC) ≥ 27.
RESULTS: CSF prevalence was significantly higher in the COVID (+) UA-NCA group than in the COVID (-) UA-NCA group (18.9% vs. 5.3%, p = 0.003). Individual CTFC values for the LAD, LCX, and RCA were also significantly higher in the COVID (+) UA-NCA group compared to the COVID (-) UA-NCA group (26.1 ± 4.3 vs. 22.4 ± 2.6 [p = 0.01], 24.3 ± 4.5 vs. 21.7 ± 2.4 [p < 0.001], and 24.3 ± 4.5 vs. 21.4 ± 2.5 [p < 0.001], respectively).
CONCLUSIONS: CSF prevalence is significantly higher in patients with a history of COVID-19, suggesting persistent microvascular impairment.